📰 Actrims News
Page 2 - Actrims News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Actrims. Real-time updates on events, politics, business and more.
October 13, 2021
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest
October 13, 2021
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib
February 25, 2021
25 febbraio 2021 14:05 Fonte: Adnkronos #chimica-e-farmacia MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD In both studies, protective antibody levels we...